Scott B. Ullem - 09 Dec 2025 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role: CVP, Chief Financial Officer
Signature: Linda J. Park, Attorney-in-Fact
Issuer symbol: EW
Transactions as of: 09 Dec 2025
Net transactions value: -$194,135
Form type: 4
Filing time: 09 Dec 2025, 17:01:36 UTC
Previous filing: 10 Nov 2025
Next filing: 05 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ullem Scott B.	CVP, Chief Financial Officer	ONE EDWARDS WAY, IRVINE	Linda J. Park, Attorney-in-Fact	09 Dec 2025	0001446989

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EW	Common Stock	Options Exercise	$456,277	+7,700	+19%	$59.26	47,598	09 Dec 2025	Direct	F1
transaction	EW	Common Stock	Sale	$650,412	-7,700	-16%	$84.47	39,898	09 Dec 2025	Direct	F1, F2
holding	EW	Common Stock						266,318	09 Dec 2025	By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EW	Employee Stock Option (Right to Acquire)	Options Exercise	$0	-7,700	-16%	$0.000000	39,000	09 Dec 2025	Common Stock	7,700	$59.26	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 29, 2025.
F2	This transaction was executed in multiple trades at prices ranging from $84.09 to $85.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.